Hoth Therapeutics, Inc. (HOTH)

$4.8

-0.12 (-2.44%)
Rating:
Recommendation:
-
Symbol HOTH
Price $4.8
Beta 0.186
Volume Avg. 0.80M
Market Cap 6.914M
Shares () -
52 Week Range 2.61-40.75
1y Target Est -
DCF Unlevered HOTH DCF ->
DCF Levered HOTH LDCF ->
ROE -120.99% Strong Sell
ROA -114.94% Strong Sell
Operating Margin -
Debt / Equity 14.90% Neutral
P/E -
P/B 0.72 Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest HOTH news


Mr. Robb Knie
Healthcare
Biotechnology
NASDAQ Capital Market

Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-003 to treat inflammatory bowel diseases, as well as acne and psoriasis; HT-004 for treatment of asthma and allergies using inhalational administration; HT-006 to treat lung diseases resulting from bacterial infections; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus. The company has license agreements with the George Washington University; the University of Maryland; Isoprene Pharmaceuticals, Inc.; the North Carolina State University; Chelexa BioSciences, Inc.; Zylö Therapeutics, Inc., and the University of Cincinnati. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is headquartered in New York, New York.